Abstract 4654
Background
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy, with no standard treatment other than splenectomy. The aim of this retrospective single-center study was to evaluate the clinical characteristics and prognosis of SMZL.
Methods
Between 2008 and 2015, we analyzed a total of 52 patients being considered as appropriate diagnostic criteria for SMZL in our hematology clinic. There were 36 (69%) female and 16 (31%) male patients. Median age was 58.8 years (range, 37-88 years). The median time of follow-up was 20.3 months (range, 3-97.7 months).
Results
We retrospectively assessed 52 patients from single center, who received splenectomy, either alone or with chemotherapy. The presence of splenomegaly (95.2%) was recorded as the most frequent symptom at diagnosis. Of the patients, 44 (84.6%) had bone marrow involvement and 11 (21.2%) had lymph nodes involvement. Tumor involvement of peripheral blood defined as the presence of absolute lymphocytosis or 5% of tumor lymphocytes in peripheral blood was detected in 10 patients (19.2%). Because of the high frequency of bone marrow involvement, most patients in the series were Ann Arbor stage IV. Data concerning the presence of hypogammaglobulinemia was obtained from only 9 patients (42.9%). Obviously, 20 patients underwent splenectomy. In 7 patients (35%) chemotherapy was received apart from splenectomy.The number of patients reaching clinical complete remission after splenectomy with/out therapy was 18 (90%) and partial remission 3 (15%). The probability of 5 year-overall survival was 87.5%±11.7%. When we analyzed the patients with splenectomy alone the probability of overall survival was 83.3%±15.2%.
Conclusions
In conclusion, although the options of new treatment modality in SMZL have been debated today, splenectomy seems to be safe and effective in controlling long-term disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract